Humanigen Inc

NASDAQ:HGEN   3:59:58 PM EDT
6.61
+0.19 (+2.96%)
4:04:43 PM EDT: $6.60 -0.01 (-0.15%)
Products, Regulatory

Humanigen Announces Oral Presentation Of Lenzilumab Phase 3 Study Results At Idweek 2021

Published: 09/29/2021 12:43 GMT
Humanigen Inc (HGEN) - Humanigen Announces Oral Presentation of Lenzilumab Live-air Phase 3 Study Results at Idweek 2021.
Humanigen Inc - Lenzilumab Significantly Improved Likelihood of Survival Without Ventilation (swov) by 54%.
Humanigen Inc - Live-air Study Achieved Its Primary Endpoint.
Humanigen Inc - in This Study, Lenzilumab Appeared to Be Safe and Well-tolerated, There Were No Serious Adverse Events (saes) Attributed to Lenzilumab.